Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Vivesto

7.22 SEK+5.87 %22.10, 17.25
Less than 1K followers

VIVE

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+5.87 %
-19.96 %
-17.77 %
-10.64 %
-38.55 %
-62.72 %
-60.59 %
-96.50 %
-99.54 %

Vivesto is a pharmaceutical company focused on developing innovative treatments for serious oncology diseases. The company is researching new therapies that can improve patient outcomes and quality of life. The company operates globally with a primary presence in Europe and North America. Vivesto was founded in 1988 and is headquartered in Uppsala, Sweden.

Read more
Market cap
79.94M SEK
Turnover
46.07K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
12.11
2026

Interim report Q3'26

11.2
2027

Annual report '26

All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release13.10.2026, 13.47

DNB Carnegie Access: Vivesto: Key congress exposure for Paccal Vet data

Vivesto
Press release13.10.2026, 08.00

Vivesto presents Paccal Vet data at the WSAVA World Congress 2026

Vivesto
Press release24.09.2026, 08.00

Vivesto presents Paccal Vet data at the Veterinary Cancer Society Annual Conference 2026

Vivesto

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release21.09.2026, 17.28

DNB Carnegie Access: Vivesto - Framsteg inom veterinärmedicin

Vivesto
Press release17.09.2026, 11.35

DNB Carnegie Access: Vivesto: Positive top-line results in cat study

Vivesto
Regulatory press release17.09.2026, 10.08

Vivesto reports positive Paccal Vet cat topline results supporting continued clinical development

Vivesto
Press release15.09.2026, 15.53

DNB Carnegie Access: Vivesto: Positive top-line results in dog study

Vivesto
Regulatory press release15.09.2026, 13.45

Vivesto’s positive dog topline results support continued development and strengthen partnering prospects for Paccal Vet

Vivesto
Press release13.08.2026, 18.48

DNB Carnegie Access: Vivesto: Largely a non-event, key readouts ahead – Q2 review

Vivesto
Press release01.07.2026, 10.04

DNB Carnegie Access: Vivesto: Cat study enrolment completed, results expected in Q4

Vivesto
Press release01.07.2026, 08.00

Vivesto completes recruitment in Paccal Vet study in cats and determines maximum tolerated dose

Vivesto
Press release26.06.2026, 13.59

DNB Carnegie Access: Vivesto: Paccal Vet top-line results expected in Q3

Vivesto
Press release26.06.2026, 08.00

Vivesto completes recruitment in Paccal Vet dog pilot study – topline results expected Q3 2026

Vivesto
Press release26.06.2026, 08.00

Vivesto completes recruitment in Paccal Vet dog pilot study – topline results expected Q3 2026

Vivesto
Press release16.06.2026, 10.30

DNB Carnegie Access: Vivesto: Positive data for Cantrixil

Vivesto
Press release16.06.2026, 08.00

Vivesto reports positive results from i.v. Cantrixil PK/toxicology study

Vivesto
Regulatory press release05.06.2026, 08.00

Vivesto appoints Björn Svanström as CFO

Vivesto
Regulatory press release29.05.2026, 08.00

New number of shares and votes in Vivesto

Vivesto
Press release26.05.2026, 06.30

DNB Carnegie Access: Vivesto: Minor model adjustments

Vivesto
Regulatory press release13.05.2026, 13.00

Vivesto announces timetable for reverse share split

Vivesto